

**Datasheet for 600-401-BT7****IFTLD1 Antibody****Overview**

<b>Description:</b>	Anti-IFTLD1 (RABBIT) Antibody - 600-401-BT7
<b>Item No.:</b>	600-401-BT7
<b>Size:</b>	100 µg
<b>Applications:</b>	ELISA, IHC, WB
<b>Reactivity:</b>	Human, Mouse, Rat
<b>Host Species:</b>	Rabbit

**Product Details**

<b>Background:</b>	The intermediate filament tail domain-containing protein (IFTLD1) was initially identified as a candidate gene for pulmonary adenoma susceptibility 1 gene in mice. Transcripts of the gene were only detected in mouse lung tissue from strains carrying the Pas1-susceptible allele. Expression of different alleles of this gene in lung cancer cell lines resulted in different levels of colony formation in in vitro colony formation assays, suggesting that allelic variants of this gene can modulate growth of human cancer cells.
<b>Synonyms:</b>	IFTLD1 Antibody, PAS1C1, Intermediate filament tail domain-containing protein 1, Lamin tail domain-containing protein 1
<b>Host Species:</b>	Rabbit
<b>Clonality:</b>	Polyclonal
<b>Format:</b>	IgG

**Target Details**

<b>Gene Name:</b>	LMNTD1
<b>Reactivity:</b>	Human, Mouse, Rat
<b>Immunogen Type:</b>	Conjugated Peptide
<b>Immunogen:</b>	Anti-IFTLD1 antibody was prepared from whole rabbit serum produced by repeated immunizations with an 19 amino acid synthetic peptide near the internal region of human IFTLD1.

<b>Purity/Specificity:</b>	Anti-IFTLD1 Antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography. At least four isoforms of IFTLD1 are known to exist; this antibody will detect all but isoform 4
<b>Relevant Links:</b>	<ul style="list-style-type: none"><li>• <a href="#">UniProtKB - Q8N9Z9</a></li><li>• <a href="#">GeneID - 160492</a></li><li>• <a href="#">NCBI - NP_001139200</a></li></ul>

## Application Details

<b>Tested Applications:</b>	ELISA, IHC, WB
<b>Application Note:</b>	Anti-IFTLD1 Antibody has been tested for use in ELISA, Western Blotting, and Immunohistochemistry. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 43 kDa in Western Blots of specific cell lysates and tissues.
<b>Assay Dilutions:</b>	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
<b>ELISA:</b>	1:10,000 - 1:20,000
<b>IHC:</b>	5 µg/mL
<b>WB:</b>	1-2 µg/mL


## Formulation

<b>Physical State:</b>	Liquid (sterile filtered)
<b>Concentration:</b>	1.0 mg/ml by UV absorbance at 280 nm
<b>Buffer:</b>	0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2
<b>Preservative:</b>	0.02% (w/v) Sodium Azide
<b>Stabilizer:</b>	None

## Shipping & Handling

<b>Shipping Condition:</b>	Dry Ice
<b>Storage Condition:</b>	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
<b>Expiration:</b>	Expiration date is one (1) year from date of receipt.


## Images



### Immunohistochemistry

Immunohistochemistry of IFTLD1.

Tissue: rat liver tissue. Primary Antibody: IFTLD1 antibody at 5 µg/mL.



### Western Blot

Western blot analysis of IFTLD1. Load: rat liver tissue lysate.

Primary Antibody: IFTLD1 antibody at (A) 1 µg/mL and (B) 2 µg/mL.

## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.